As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
8 Analysts have issued a Ikena Oncology Inc forecast:
8 Analysts have issued a Ikena Oncology Inc forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -54 -54 |
27%
27%
|
|
| EBIT (Operating Income) EBIT | -55 -55 |
28%
28%
|
|
| Net Profit | -49 -49 |
28%
28%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Mark Manfredi |
| Employees | 9 |
| Founded | 2016 |
| Website | www.ikenaoncology.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


